Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience.

Autor:	Tkhilaishvili T; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; Department of Tropical Medicine and Infectious Diseases, University of Rostock, Rostock, Germany. Electronic address: tkhilaishvili@dhzb.de., Potapov E; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany., Starck C; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany., Mulzer J; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany., Falk V; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany; Department of Cardiovascular Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland., Trampuz A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Center for Musculoskeletal Surgery, Berlin, Germany., Schoenrath F; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Jazyk:	angličtina
Zdroj:	The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2022 May; Vol. 41 (5), pp. 551-555. Date of Electronic Publication: 2022 Jan 26.
DOI:	10.1016/j.healun.2022.01.018
Abstrakt:	Conventional antimicrobials have low or no activity against multidrug-resistant or chronic implant-associated infections. Lytic bacteriophages can rapidly and selectively kill bacteria, and can be combined with antibiotics. However, clinical experience of bacteriophage therapy in patients with cardiovascular infections is limited. We documented the outcome and safety of intravenous and local adjunctive bacteriophage therapy, to treat chronic relapsing cardiovascular implant infections at our institution. Competing Interests: Disclosure statement The authors have no conflicts of interest to declare. (Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu